Search results
Results from the WOW.Com Content Network
Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug. [7] It acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor. [8]It was developed by Astellas Pharma.
This page was last edited on 19 September 2021, at 22:03 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The current version of the IEC standard is the second edition dated 2008-12-09. [1] The basic standards (61000-4) are usually called by product or family specific standards, which use these basic standards as a common reference.
CISPR is the acronym of Comité International Spécial des Perturbations Radio, [1] or the International Special Committee for Radio Protection of IEC. CISPR Standards aim to the protection of radio reception in the range 9 kHz to 400 GHz from interference caused by operation of electrical or electronic appliances and systems in the electromagnetic environment.
Like all compliance testing, it is important that the test equipment, including the test chamber or site and any software used, be properly calibrated and maintained. Typically, a given run of tests for a particular piece of equipment will require an EMC test plan and a follow-up test report. The full test program may require the production of ...
It would be nice to have this list extended with IEC61000 and CISPR data. I will make an attempt to do so . LHOON 06:46, 14 March 2006 (UTC) I have added a number of documents, the list is still incomplete though. LHOON 12:02, 14 March 2006 (UTC) Alfredemv 23:54, 8 September 2007 (UTC)
The study was designed and powered to test for non-inferiority and superiority of upadacitinib versus adalimumab clinically and functionally. At week 12, both primary endpoints were met for upadacitinib versus placebo (p≤0.001). ACR20 was achieved by 71% versus 36%, and DAS28CRP<2.6 by 29% versus 6%.
Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor primarily used for the treatment of ALK positive metastatic NSCLC. [8] [9] Previously, it was only indicated for patients who had developed resistant to crizotinib, another ALK inhibitor, but has since had its usage expanded to serve as a primary option for metastatic NSCLC.